Terms: = Germ cell tumor AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Staging
42 results:
1. Modern diagnostics and treatment of Merkel cell carcinoma.
Weilandt J; Peitsch WK
J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1546. PubMed ID: 37875785
[TBL] [Abstract] [Full Text] [Related]
2. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to pd-1 checkpoint inhibition in melanoma metastases.
Chatziioannou E; Roßner J; Aung TN; Rimm DL; Niessner H; Keim U; Serna-Higuita LM; Bonzheim I; Kuhn Cuellar L; Westphal D; Steininger J; Meier F; Pop OT; Forchhammer S; Flatz L; Eigentler T; Garbe C; Röcken M; Amaral T; Sinnberg T
EBioMedicine; 2023 Jul; 93():104644. PubMed ID: 37295047
[TBL] [Abstract] [Full Text] [Related]
3. Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease.
Siqueira SOM; Campos-do-Carmo G; Dos Santos ALS; Martins C; de Melo AC
An Bras Dermatol; 2023; 98(3):277-286. PubMed ID: 36870886
[TBL] [Abstract] [Full Text] [Related]
4. Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma.
Liu D; Yang F; Zhang T; Mao R
J Transl Med; 2023 Jan; 21(1):57. PubMed ID: 36717900
[TBL] [Abstract] [Full Text] [Related]
5. Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome.
Attrill GH; Lee H; Tasker AT; Adegoke NA; Ferguson AL; da Silva IP; Saw RPM; Thompson JF; Palendira U; Long GV; Ferguson PM; Scolyer RA; Wilmott JS
Front Immunol; 2022; 13():979993. PubMed ID: 36003398
[TBL] [Abstract] [Full Text] [Related]
6. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.
Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Basset-Seguin N; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Forsea AM; Grob JJ; Hoeller C; Kaufmann R; Kelleners-Smeets N; Lallas A; Lebbé C; Lytvynenko B; Malvehy J; Moreno-Ramirez D; Nathan P; Pellacani G; Saiag P; Stratigos AJ; Van Akkooi ACJ; Vieira R; Zalaudek I; Lorigan P;
Eur J Cancer; 2022 Jul; 170():256-284. PubMed ID: 35623961
[TBL] [Abstract] [Full Text] [Related]
7. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.
Ascierto PA; Warner AB; Blank C; Caracò C; Demaria S; Gershenwald JE; Khushalani NI; Long GV; Luke JJ; Mehnert JM; Robert C; Rutkowski P; Tawbi HA; Osman I; Puzanov I
J Transl Med; 2022 May; 20(1):200. PubMed ID: 35538491
[TBL] [Abstract] [Full Text] [Related]
8. Toxicity profile of treatment with pd-1 inhibitors for lung cancer, melanoma and renal cell carcinoma: A real-world Brazilian study.
Duarte HS; Veiga CRP; Veiga CP; Wainstein AJA; Drummond-Lage AP
Int Immunopharmacol; 2022 Jul; 108():108727. PubMed ID: 35397393
[TBL] [Abstract] [Full Text] [Related]
9. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-pd-1 therapy.
Eckardt J; Schroeder C; Martus P; Armeanu-Ebinger S; Kelemen O; Gschwind A; Bonzheim I; Eigentler T; Amaral T; Ossowski S; Rieß O; Flatz L; Garbe C; Forschner A
J Cancer Res Clin Oncol; 2023 Feb; 149(2):833-840. PubMed ID: 35192052
[TBL] [Abstract] [Full Text] [Related]
10. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate pd-1 Resistance Signature (IPRES).
Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
[TBL] [Abstract] [Full Text] [Related]
11. Clinical Predictors of Response to Anti-pd-1 First-Line Treatment in a Single-Centre Patient Cohort: A Real-World Study.
Di Pietro FR; Verkhovskaia S; Mastroeni S; Carbone ML; Abeni D; Di Rocco CZ; Samà N; Zappalà AR; Marchetti P; De Galitiis F; Failla CM; Fortes C
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e18-e24. PubMed ID: 34563446
[TBL] [Abstract] [Full Text] [Related]
12. [Melanoma : the patient's care pathway. From diagnosis to therapy].
Absil G; Damsin T; Lebas E; Libon F; Somja J; Collins P; Reginster MA; Quatresooz P; Rorive A; Marchal N; Jacquemin D; Bous A; Piret P; Nikkels AF
Rev Med Liege; 2021 May; 76(5-6):489-495. PubMed ID: 34080385
[TBL] [Abstract] [Full Text] [Related]
13. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract] [Full Text] [Related]
14. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
Ascierto PA; Atkins MB; Eggermont AM; Gershenwald JE; Grob JJ; Hamid O; Sondak VK; Sosman JA; Tawbi HA; Weber JS; Caracò C; Osman I; Puzanov I
J Transl Med; 2021 Apr; 19(1):142. PubMed ID: 33827575
[TBL] [Abstract] [Full Text] [Related]
15. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).
Broman KK; Hughes T; Dossett L; Sun J; Kirichenko D; Carr MJ; Sharma A; Bartlett EK; Nijhuis AAG; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; Frank J; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Farma JM; Deneve JL; Fleming MD; Perez MC; Lowe MC; Olofsson Bagge R; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras J; Teras RM; Farrow NE; Beasley G; Hui JYC; Been L; Kruijff S; Kim Y; Naqvi SMH; Sarnaik AA; Sondak VK; Zager JS
Cancer; 2021 Jul; 127(13):2251-2261. PubMed ID: 33826754
[TBL] [Abstract] [Full Text] [Related]
16. Novel adjuvant options for cutaneous melanoma.
Dimitriou F; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
[TBL] [Abstract] [Full Text] [Related]
17. Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data.
Zhang X; Liang Y
Biomed Res Int; 2021; 2021():8197936. PubMed ID: 33506034
[TBL] [Abstract] [Full Text] [Related]
18. Treatment of gestational trophoblastic disease in the 2020s.
Clark JJ; Slater S; Seckl MJ
Curr Opin Obstet Gynecol; 2021 Feb; 33(1):7-12. PubMed ID: 33337613
[TBL] [Abstract] [Full Text] [Related]
19. Safety of pembrolizumab for resected stage III melanoma.
Pham F; Dalle S
Expert Opin Drug Saf; 2020 Oct; 19(10):1221-1227. PubMed ID: 32799585
[TBL] [Abstract] [Full Text] [Related]
20. Adjuvant immunotherapy: the sting in the tail.
Higham CE; Chatzimavridou-Grigoriadou V; Fitzgerald CT; Trainer PJ; Eggermont AMM; Lorigan P
Eur J Cancer; 2020 Jun; 132():207-210. PubMed ID: 32388064
[TBL] [Abstract] [Full Text] [Related]
[Next]
